BridgeBio Pharma, Inc. (2CL.F)
| Previous Close | 22.11 |
| Open | 22.73 |
| Bid | 22.99 x N/A |
| Ask | 23.46 x N/A |
| Day's Range | 22.73 - 23.25 |
| 52 Week Range | 11.70 - 39.72 |
| Volume | |
| Avg. Volume | 30 |
| Market Cap | 4.278B |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.68 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.40 |
ZacksWill BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 19 new employees in restricted stock units for an aggregate of 93,088 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s rest
- GlobeNewswire
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demonstrate that targeting near-complete transthyretin (TTR) stabilization with acoramidis may enable cardiac remodeling and functional recovery in patients with ATTR-CM - These results are the first prospective, longitudinal evaluation of cardiac structure and function by CMR imaging in a
